The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Stefan J. Faderl

Department of Leukemia

The University of Texas MD Anderson Cancer Center

Houston

Texas

[email]@mdanderson.org

Name/email consistency: high

 
 
 
 
 
 
 

Affiliation

  • Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas. 2002 - 2012

References

  1. Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients. Faderl, S., Ravandi, F., Huang, X., Wang, X., Jabbour, E., Garcia-Manero, G., Kadia, T., Ferrajoli, A., Konopleva, M., Borthakur, G., Burger, J., Feliu, J., Kantarjian, H.M. Cancer (2012) [Pubmed]
  2. Clofarabine Plus Cytarabine Compared With Cytarabine Alone in Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia: Results From the CLASSIC I Trial. Faderl, S., Wetzler, M., Rizzieri, D., Schiller, G., Jagasia, M., Stuart, R., Ganguly, S., Avigan, D., Craig, M., Collins, R., Maris, M., Kovacsovics, T., Goldberg, S., Seiter, K., Hari, P., Greiner, J., Vey, N., Recher, C., Ravandi, F., Wang, E.S., Vasconcelles, M., Huebner, D., Kantarjian, H.M. J. Clin. Oncol. (2012) [Pubmed]
  3. A randomized study of 2 dose levels of intravenous clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome. Faderl, S., Garcia-Manero, G., Jabbour, E., Ravandi, F., Borthakur, G., Estrov, Z., Gandhi, V., Byrd, A.L., Kwari, M., Cortes, J., Kantarjian, H.M. Cancer (2012) [Pubmed]
  4. Kit inhibitor APcK110 extends survival in an AML xenograft mouse model. Faderl, S., Bueso-Ramos, C., Liu, Z., Pal, A., Bornmann, W., Ciurea, D.V., Harris, D., Hazan-Halevy, I., Kantarjian, H.M., Estrov, Z. Invest. New. Drugs (2011) [Pubmed]
  5. Augmented hyper-CVAD based on dose-intensified vincristine, dexamethasone, and asparaginase in adult acute lymphoblastic leukemia salvage therapy. Faderl, S., Thomas, D.A., O'Brien, S., Ravandi, F., Garcia-Manero, G., Borthakur, G., Ferrajoli, A., Verstovsek, S., Ayoubi, M., Rytting, M., Feliu, J., Kantarjian, H.M. Clin. Lymphoma. Myeloma. Leuk (2011) [Pubmed]
  6. Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome. Faderl, S., Garcia-Manero, G., Estrov, Z., Ravandi, F., Borthakur, G., Cortes, J.E., O'Brien, S., Gandhi, V., Plunkett, W., Byrd, A., Kwari, M., Kantarjian, H.M. J. Clin. Oncol. (2010) [Pubmed]
  7. Adult acute lymphoblastic leukemia: concepts and strategies. Faderl, S., O'Brien, S., Pui, C.H., Stock, W., Wetzler, M., Hoelzer, D., Kantarjian, H.M. Cancer (2010) [Pubmed]
  8. Last exit clofarabine? Faderl, S. Leuk. Lymphoma (2009) [Pubmed]
  9. Kit inhibitor APcK110 induces apoptosis and inhibits proliferation of acute myeloid leukemia cells. Faderl, S., Pal, A., Bornmann, W., Albitar, M., Maxwell, D., Van, Q., Peng, Z., Harris, D., Liu, Z., Hazan-Halevy, I., Kantarjian, H.M., Estrov, Z. Cancer Res. (2009) [Pubmed]
  10. Treatment of B-cell chronic lymphocytic leukemia with nonchemotherapeutic agents: experience with single-agent and combination therapy. Faderl, S., Ferrajoli, A., Frankfurt, O., Pettitt, A. Leukemia (2009) [Pubmed]
  11. Potential role of novel nucleoside analogs in the treatment of acute myeloid leukemia. Faderl, S., Gandhi, V., Kantarjian, H.M. Curr. Opin. Hematol. (2008) [Pubmed]
  12. A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Faderl, S., Ravandi, F., Huang, X., Garcia-Manero, G., Ferrajoli, A., Estrov, Z., Borthakur, G., Verstovsek, S., Thomas, D.A., Kwari, M., Kantarjian, H.M. Blood (2008) [Pubmed]
  13. Clofarabine combinations as acute myeloid leukemia salvage therapy. Faderl, S., Ferrajoli, A., Wierda, W., Huang, X., Verstovsek, S., Ravandi, F., Estrov, Z., Borthakur, G., Kwari, M., Kantarjian, H.M. Cancer (2008) [Pubmed]
  14. Atiprimod blocks phosphorylation of JAK-STAT and inhibits proliferation of acute myeloid leukemia (AML) cells. Faderl, S., Ferrajoli, A., Harris, D., Van, Q., Kantarjian, H.M., Estrov, Z. Leuk. Res. (2007) [Pubmed]
  15. Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older. Faderl, S., Verstovsek, S., Cortes, J., Ravandi, F., Beran, M., Garcia-Manero, G., Ferrajoli, A., Estrov, Z., O'Brien, S., Koller, C., Giles, F.J., Wierda, W., Kwari, M., Kantarjian, H.M. Blood (2006) [Pubmed]
  16. Monoclonal antibody combinations in CLL: evolving strategies. Faderl, S., O'Brien, S., Keating, M.J. Best. Pract. Res. Clin. Haematol (2006) [Pubmed]
  17. Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Faderl, S., Gandhi, V., O'Brien, S., Bonate, P., Cortes, J., Estey, E., Beran, M., Wierda, W., Garcia-Manero, G., Ferrajoli, A., Estrov, Z., Giles, F.J., Du, M., Kwari, M., Keating, M., Plunkett, W., Kantarjian, H. Blood (2005) [Pubmed]
  18. Treatment of chronic lymphocytic leukemia. Faderl, S.J., Keating, M.J. Curr. Hematol. Rep. (2005) [Pubmed]
  19. The role of clofarabine in hematologic and solid malignancies--development of a next-generation nucleoside analog. Faderl, S., Gandhi, V., Keating, M.J., Jeha, S., Plunkett, W., Kantarjian, H.M. Cancer (2005) [Pubmed]
  20. Drug insight: emerging new drugs in the treatment of myelodysplastic syndromes. Faderl, S., Kantarjian, H.M. Nature Clinical Practice. Oncology (2005) [Pubmed]
  21. The evolving role of alemtuzumab in management of patients with CLL. Faderl, S., Coutré, S., Byrd, J.C., Dearden, C., Denes, A., Dyer, M.J., Gregory, S.A., Gribben, J.G., Hillmen, P., Keating, M., Rosen, S., Venugopal, P., Rai, K. Leukemia (2005) [Pubmed]
  22. Hematopoietic recovery following induction therapy of acute leukemias: prognostic implications and a new look at the definition of remission. Faderl, S., Estrov, Z. Leuk. Lymphoma (2004) [Pubmed]
  23. Novel therapies for myelodysplastic syndromes. Faderl, S., Kantarjian, H.M. Cancer (2004) [Pubmed]
  24. Monitoring of minimal residual disease in chronic myeloid leukemia. Faderl, S., Hochhaus, A., Hughes, T. Hematol. Oncol. Clin. North Am. (2004) [Pubmed]
  25. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Faderl, S., Thomas, D.A., O'Brien, S., Garcia-Manero, G., Kantarjian, H.M., Giles, F.J., Koller, C., Ferrajoli, A., Verstovsek, S., Pro, B., Andreeff, M., Beran, M., Cortes, J., Wierda, W., Tran, N., Keating, M.J. Blood (2003) [Pubmed]
  26. Commentary: effect of flavonoids on normal and leukemic cells. Faderl, S., Estrov, Z. Leuk. Res. (2003) [Pubmed]
  27. The biology and therapy of adult acute lymphoblastic leukemia. Faderl, S., Jeha, S., Kantarjian, H.M. Cancer (2003) [Pubmed]
  28. Philadelphia chromosome-positive acute lymphoblastic leukemia- current concepts and future perspectives. Faderl, S., Garcia-Manero, G., Thomas, D.A., Kantarjian, H.M. Rev. Clin. Exp. Hematol (2002) [Pubmed]
 
WikiGenes - Universities